Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | KHK | P50053 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158111 | 0.85 | HRH3 (0.36) | HRH3HPGDKMT2ASMN1; SMN2HTR6 | |
| SCHEMBL18202930 | 0.84 | HRH3 (0.33) | HRH3CHRM3 | |
| SCHEMBL2165016 | 0.83 | HRH3 (0.33) | HRH3HPGDKMT2ASMN1; SMN2HTR6 | |
| SCHEMBL4825714 | 0.83 | HTR6 (0.41) | HRH3HPGDKMT2ASMN1; SMN2HTR6 | |
| SCHEMBL8314294 | 0.79 | SIGMAR1 (0.37) | HRH3 | |
| SCHEMBL17692977 | 0.79 | HRH3 (0.39) | HRH3HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL521969 | 0.78 | HRH3 (0.39) | HRH3HPGDKMT2ASMN1; SMN2HTR6 | |
| SCHEMBL13381568 | 0.78 | CYP2D6 (0.40) | HRH3HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL15710120 | 0.78 | HRH3 (0.34) | HRH3HPGDKMT2ASMN1; SMN2HTR6 | |
| SCHEMBL15710119 | 0.78 | HRH3 (0.34) | HRH3HPGDKMT2ASMN1; SMN2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3957633-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2022-02-23 | — | — | EP | disclosed |
| US-7625886-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-7449485-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1940824-A1 | SELECTED CGRP ANTAGONISTS METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | US | disclosed |
| US-7358251-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1487811-B1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070099903-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
| WO-2007045672-A1 | SELECTED CGRP ANTAGONISTS METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-26 | — | — | WO | disclosed |
| US-7030115-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060074085-A1 | N-sulfonylurea apoptosis promoters | ABBVIE INC. | 2006-04-06 | — | — | US | disclosed |
| EP-1487811-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030236247-A1 | N-sulfonylurea apoptosis promoters | ABBVIE INC. | 2003-12-25 | — | — | US | disclosed |
| WO-2003080586-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | BAX, BCL2, BAD | HRH3 4437/4885HPGD 2339/4885KMT2A 3213/4885 |
| US-20060074085-A1 | N-sulfonylurea apoptosis promoters | BAX, BCL2, BAD | HRH3 4437/4885HPGD 2339/4885KMT2A 3213/4885 |
| US-20070099903-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | HRH3 46/4885HPGD 437/4885KMT2A 4803/4885 |
| US-20030236247-A1 | N-sulfonylurea apoptosis promoters | BAX, BCL2, AIFM1 | HRH3 4509/4885HPGD 2811/4885KMT2A 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.